Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts

Osteoporosis International

Volumn 25, Issue 10, 2014, Pages 2453-2463

  Pathak, J L ^a,b   Bravenboer, N ^c   Verschueren, P ^b   Lems, W F ^c   Luyten, F P ^b   Klein Nulend, J ^a   Bakker, A D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; IL 6; OPG; Osteogenic differentiation; Osteoporosis; RANKL

Indexed keywords

COLLAGEN TYPE 1; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8; KI 67 ANTIGEN; LEFLUNOMIDE; METHOTREXATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; ALKALINE PHOSPHATASE; AUTACOID; SIGNAL PEPTIDE;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DNA CONTENT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; REMISSION; RHEUMATOID ARTHRITIS; SERUM; AGED; BIOSYNTHESIS; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; ALKALINE PHOSPHATASE; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; REMISSION INDUCTION;

EID: 84919462289     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2779-1     Document Type: Article

References (38)

1. Mielants H, Van den Bosch F (2009) Extra-articular manifestations. Clin Exp Rheumatol 27(Suppl 55):S56–S61
2. Vis M, Güler-Yüksel M, Lems WF (2013) Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int 10:2541–2553
3. van Staa L, Geusens P, Bijlsma JWJ, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112
4. Orstavik RE, Haugeberg G, Mowinckel P, Hoiseth A, Uhlig T, Falch JA (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population based controls. Arch Int Med 164:420–425
5. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalized bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27
6. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17S
7. van der Heijde DM (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34(Suppl 2):74–78
8. Schett G (2006) Rheumatoid arthritis inflammation and bone loss. Wien Med Wochenschr 156:34–41
9. Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC (1993) Bone metabolism in rheumatoid arthritis: relation to disease activity. Br J Rheumatol 32:387–391
10. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537–3545
11. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M (2007) Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol 25:584–592
12. Chung SJ, Kwon YJ, Park MC, Park YB, Lee SK (2011) The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 52:113–120
13. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y (2010) Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Jt Bone Spine 77:201–205
14. Bakker AD, Silva VC, Krishnan R, Bacabac RG, Blaauboer ME, Lin YC, Marcantonio RA, Cirelli JA, Klein-Nulend J (2009) Tumor necrosis factor alpha and interleukin-1beta modulate calcium and nitric oxide signaling in mechanically stimulated osteocytes. Arthritis Rheum 60:3336–3345
15. Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J (2010) Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69:284–290
16. Luyten FP, Lories RJ, Verschueren P, d Vlam K, Westhovens R (2006) Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 20:829–848
17. Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656–664
18. Kulkarni RN, Bakker AD, Everts V, Klein-Nulend J (2012) Mechanical loading prevents the stimulating effect of IL-1beta on osteocyte-modulated osteoclastogenesis. Biochem Biophys Res Commun 420:11–16
19. Bakker AD, Kulkarni RN, Klein-Nulend J, Lems WF (2014) IL-6 alters osteocyte signaling toward osteoblasts but not osteoclasts. J Dent Res 93:394–399
20. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A (2006) Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54:3551–3563
21. Klein-Nulend J, Sterck JGH, Semeins CM, Lips P, Joldersma M, Baart JA, Burger EH (2002) Donor age and mechanosensitivity of human bone cells. Osteoporos Int 13:137–146
22. Langan TJ, Chou RC (2011) Synchronization of mammalian cell cultures by sera deprivation. Methods Mol Biol 761:75–83
23. Lowry OH (1995) Micromethods for the asay of enzyme II specific procedure. Alkaline phosphatase. Meth Enzymol 4:371
24. Bloemen V, de Vries TJ, Schoenmaker T, Everts V (2009) Intercellular adhesion molecule-1 clusters during osteoclastogenesis. Biochem Biophys Res Commun 385:640–645
25. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH, Dijkmans BA, Lems WF (2003) Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 48:2996–2997
26. Caparbo VF, Prada F, Silva CA, Regio PL, Pereira RM (2009) Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts “in vitro”. Clin Rheumatol 28:71–77
27. Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, Li ZG (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 38:821–827
28. Matzelle MM, Gallant MA, Condon KW, Walsh NC, Manning CA, Stein GS, Lian JB, Burr DB, Gravallese EM (2012) Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 64:1540–1550
29. Abbas S, Zhang Y-H, Clohisy JC, Abu-Amer Y (2003) Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 22:33–41
30. Hughes FJ, Howells GL (1993) Interleukin-6 inhibits bone formation in vitro. Bone Miner 21:21–28
31. Chaudhary LR, Spelsberg TC, Riggs BL (1992) Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1 beta and tumor necrosis factor-alpha: lack of regulation by 17 beta-estradiol. Endocrinology 130:2528–2534
32. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499
33. Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D, Morandi L, De Simone M, Rucci N, Bertini E, Bianchi ML, De Benedetti F, Teti A (2011) Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 26:1891–1903
34. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17:1235–1241
35. Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC (1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110:559–574
36. King TJ, Georgiou KR, Cool JC, Scherer MA, Ang ES, Foster BK, Xu J, Xian CJ (2012) Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation. Am J Pathol 181:121–129
37. Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J (2010) Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. Ann Rheum Dis 69:1117–1122
38. Verschueren P, Esselens G, Westhovens R (2008) Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 47:59–64